Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Interest & Investment Income (2021 - 2025)

Allogene Therapeutics' Interest & Investment Income history spans 5 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 41.45% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $18.7 million, down 20.24%, while the annual FY2024 figure was $20.2 million, 10.08% up from the prior year.
  • Interest & Investment Income for Q3 2025 was $3.9 million at Allogene Therapeutics, down from $6.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6.7 million in Q3 2024 and bottomed at $186000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $5.0 million (2024), against an average of $3.9 million.
  • The largest annual shift saw Interest & Investment Income surged 519.26% in 2023 before it plummeted 51.68% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $186000.0 in 2021, then skyrocketed by 438.71% to $1.0 million in 2022, then soared by 525.25% to $6.3 million in 2023, then tumbled by 51.68% to $3.0 million in 2024, then rose by 29.7% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Interest & Investment Income are $3.9 million (Q3 2025), $6.2 million (Q2 2025), and $5.5 million (Q1 2025).